Scilex Holding Company (SCLX)

Healthcare Drug Manufacturers - General

6.80 $

Closing price · As of: 24. Jul 2026

Appears in These Scanners

This stock currently matches 8 of our scanner strategies — each hit links to the scanner.

Momentum & Trend

Above the 50- & 200-SMA Gary Antonacci: Dual Momentum (Stock Adaptation) High ADR (≥5%) Power Trend Stan Weinstein: Stage 3

Risk & Weakness

Bankruptcy Study: Stacked Warning Signals Going Concern (Distress Proxy) Insolvency Radar: Cash Running Low

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners

Basics

Market Cap

0.1$B

Shares Outstanding

7Mio.

Float

73.7%

Beta

1.7

Performance

Perf. 1M

73.70%

Perf. 3M

95.40%

Perf. 6M

-9.40%

YTD Performance (%)

-9.40%

52-Week-High Distance

-79.3%

Valuation

P/E

–

Forward P/E

2.7

PEG

–

P/B

–

P/S

1.5

EV/EBITDA

-2.6

Price/FCF

–

Profitability

Gross Margin

59.7%

EBIT Margin

–

Net Margin

0.0%

Return on Equity

0.0%

Return on Assets

-92.8%

Balance Sheet & Safety

Equity Ratio

–

Debt/Equity

–

warning zone

Altman Z

-25.95

Piotroski

4 von 9

Growth

Sales Growth Last Quarter

72.10%

EPS Growth Last Quarter

0.00%

Sales Growth (Year)

-46.54%

Forward Sales Growth

186.31%

Forward EPS Growth

182.00%

Quality & Screener

Stage

RS Rating

EPS Rating

Piotroski

4 von 9

Fundamental Rating

D (-20 von 100)

warning zone

Altman Z

-25.95

AI Rating

Neutral

Scilex verkauft nicht-opioide Schmerzmittel; im eigenen Geschäft kommt KI nicht vor: keine KI-Umsatzquelle, kein belegter operativer KI-Einsatz. Der 10-K 2025 enthält nur den generischen Risikoabschnitt »Risks Related to Artificial Intelligence« ohne konkreten Bezug zum eigenen Geschäftsmodell (zählt laut Kriterienkatalog nicht als »bedroht«); der 10-Q Q1 2026 nennt lediglich ein unverbindliches Term Sheet über eine KI-Apotheken-Plattform eines Partners (Wellgistics/DelivMeds AI). Die KI-Anmutung der Aktie stammt allein aus dem Namen der Finanzbeteiligung Datavault AI (~48 Prozent, per Bitcoin bezahlt) — eine Beteiligung ist kein KI-Produktumsatz. Negativ-Befund per Volltext-Prüfung von 2×10-K und 4×10-Q auf »artificial intelligence«, »machine learning«, »generative«: in den Filings vor GJ 2025 null Treffer (alle »generative«-Funde sind »regenerative/degenerative«-Fehltreffer aus der Medizin).

View the full file — quotes, sources, reviewed filings

Filings Reviewed: 10-Q 2026-05-20 · 10-Q 2025-11-14 · 10-Q 2025-08-13 · 10-Q 2025-05-14 · 10-K 2026-04-10 · 10-K 2025-03-31

Rated on July 8, 2026 · How the Rating Is Built

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Sales Per Quarter ($M)

Earnings Per Share Per Quarter ($)

Net Margin Per Quarter (%)

Operating Cash Flow Per Quarter ($M)

Free Cash Flow Per Quarter ($M)

Sales Growth vs. Year-Ago Quarter (%)

Price Change in Quarter (%)

Quarterly Figures

Quarterly Figures
Quarter	EPS (Earnings Per Share)	EPS YoY (%)	Sales ($M)	Sales YoY (%)	Net Margin (%)	OCF ($M)	FCF ($M)
2024: Q4	-0.92	–	15	10.70	-43.40	3	2
2025: Q1	-3.71	–	5	-54.00	-521.20	6	6
2025: Q2	-12.24	–	10	-39.50	-869.70	7	7
2025: Q3	-36.58	–	11	-26.80	-2,435.90	8	9
2025: Q4	-4.71	–	5	-67.80	-690.80	-18	-18
2026: Q1	-6.15	–	9	72.10	-502.40	-1	-4

What Do These Terms Mean?

EPS (Earnings Per Share):: Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):: Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:: All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:: What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):: The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):: Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

About the Company

Scilex Holding Company konzentriert sich auf Erwerb, Entwicklung und Vermarktung nicht-opioider Schmerzmanagementprodukte zur Behandlung akuter und chronischer Schmerzen. Zu den kommerziellen Produkten gehört ZTlido (Lidocain-topisches System) 1.

Employees	34
Headquarters	Palo Alto, CA
Website	scilexholding.com
IPO Date	5. Mar 2021
Next Earnings	12. Aug 2026

Management

Management
Name	Title	Birth Year
Henry H. Ji Ph.D.	CEO, President & Executive Chairman	1964
Stephen Ma	Senior VP, CFO, COO, Corporate Secretary & Director	1973
Suketu D. Desai Ph.D.	Interim Chief Technical Officer & Senior VP	1966
Gigi DeGuzman	VP & Chief People Officer	–
Suresh K. Khemani	Senior VP, Chief Commercial Officer & GM of Scilex Pharma	1960
Dmitri V. Lissin M.D.	Senior VP of Clinical Development and Medical Affairs & Interim Chief Medical Officer	1959

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Chart

Interactive price chart (TradingView).

Data as of: July 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.